An Observational Post-Marketing Surveillance Study on the Status and Factors for the Development of Peripheral Neuropathy in Patients With HER2-Negative Inoperable or Recurrent Breast Cancer in Japan.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Eribulin (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 03 Jan 2017 Planned End Date changed from 1 Feb 2018 to 1 Mar 2019.
- 03 Jan 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Mar 2018.
- 03 Jan 2017 Status changed from recruiting to active, no longer recruiting.